COTA and Sanofi Forge Partnership to Enhance Oncology Trials with AI and Real-World Data

18 April 2024 | Thursday | News

The collaboration aims to speed up cancer trials, especially for multiple myeloma, using advanced analytics to improve clinical outcomes and patient care.
Image Source : Public Domain

Image Source : Public Domain

COTA, a leader in real-world data (RWD) and analytics for oncology, today announced a strategic collaboration with Sanofi to use RWD and artificial intelligence (AI) to increase the speed of oncology trials, including for multiple myeloma. The partnership will be valuable to understand clinical outcomes that may ultimately be beneficial for patients living with cancer.

COTA’s RWD offers critical insights into effective cancer treatment pathways and will provide valuable context on key patient populations.

“Our collaboration with Sanofi has the potential to enable more patients and their families to benefit from breakthrough treatments in an expedited time frame,” said Dr. C.K. Wang, an oncologist and COTA’s chief medical officer. “We are providing high-quality RWD enabled by new AI-based tools to accelerate pharmaceutical research and improve patient care.”

The project will focus on a series of questions pertinent and relevant to multiple myeloma seeking to develop a deeper understanding of the increasingly complex treatment landscape of the disease. Potential results of this partnership could impact and guide future clinical study designs as well as inform the interpretation of results of ongoing and future trials within the context of the current standard of care for multiple myeloma patients.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in